Mené sur 83 patients atteints d'un cancer et présentant des douleurs liées à la maladie, cet essai randomisé évalue, en fonction du profil d'administration intraveineuse (de type "push" ou "piggyback"), l'efficacité analgésique ainsi que les effets indésirables de l'hydromorphone et le risque d'usage abusif

Abuse potential and analgesic efficacy of intravenous hydromorphone bolus administration among hospitalized patients with cancer pain: A double-blind, double dummy, randomized crossover trial

Arthur, Joseph A. ; Reddy, Akhila ; Popat, Uday ; Halm, Josiah ; Vaughan-Adams, Nicole ; Myers, Alan ; Yang, Peiying ; De Moraes, Aline Rozman ; Laureano, Raul ; Lopez-Quinones, Irma ; Urbauer, Diana ; Hui, David ; Bruera, Eduardo

Background : There is much concern that opioids administered as intravenous (iv) bolus for pain relief may inadvertently increase their risk for abuse. However, there is insufficient data to support this. The authors compared the abuse liability potential, analgesic efficacy, and adverse effect profile of fast (iv push) versus slow (iv piggyback) administration of iv hydromorphone among hospitalized patients requiring iv opioids for pain. Methods : In this double-blind, double dummy, [...]

Cet article passe en revue les stratégies de prise en charge des effets indésirables chez les patients recevant, pour un cancer du poumon à petites cellules préalablement traité, le tarlatamab, un anticorps bispécifique engageant les lymphocytes T et ciblant les récepteurs DLL3 et CD3

Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3–targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer

Sands, Jacob M. ; Champiat, Stéphane ; Hummel, Horst-Dieter ; Paulson, Kelly G. ; Borghaei, Hossein ; Alvarez, Jean Bustamante ; Carbone, David P. ; Carlisle, Jennifer W. ; Choudhury, Noura J. ; Clarke, Jeffrey M. ; Gadgeel, Shirish M. ; Izumi, Hiroki ; Navarro, Alejandro ; Lau, Sally C. M. ; Lammers, Philip E. ; Huang, Shuang ; Hamidi, Ali ; Mukherjee, Sujoy ; Owonikoko, Taofeek K.

Tarlatamab is a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 (DLL3) and the cluster of differentiation 3 (CD3) molecule. In the phase 2 DeLLphi-301 trial of tarlatamab for patients with previously treated small cell lung cancer, tarlatamab 10 mg every 2 weeks achieved durable responses and encouraging survival outcomes. Analyses of updated safety data from the DeLLphi-301 trial demonstrated that the most common treatment-emergent adverse events were cytokine release [...]

Menée à partir de données du registre norvégien des cancers portant sur 3 911 patientes atteintes d'un cancer épithélial de l'ovaire (âge : 40 ans ou plus), cette étude évalue l'association entre l'utilisation de bêta-bloquants avant le diagnostic de la maladie et la survie

Beta-blockers and epithelial ovarian cancer survival: A Norwegian population-based cohort study

Löfling, Leif Lukas ; Støer, Nathalie C. ; Sloan, Erica K. ; Nafisi, Sara ; Fortner, Renée Turzanski ; Botteri, Edoardo

Cancer diagnosis and therapy cause stress to the body. Preclinical studies have shown that stress hormones can stimulate tumor progression and metastasis by interacting with

Menée à partir de données 2004-2021 du registre californien des cancers, cette étude examine les tendances de l'incidence des cancers de la prostate et des taux de mortalité par stade tumoral, âge, origine ethnique et région

Trends in Prostate Cancer Incidence and Mortality Rates

Van Blarigan, Erin L. ; McKinley, Meg A. ; Washington, Samuel L., III ; Cooperberg, Matthew R. ; Kenfield, Stacey A. ; Cheng, Iona ; Gomez, Scarlett L.

Importance : Incidence of distant stage prostate cancer is increasing in the United States. Research is needed to understand trends by social and geographic factors. Objective : To examine trends in prostate cancer incidence and mortality rates in California by stage, age, race and ethnicity, and region. Design, Setting, and Participants : This cohort study used mortality data from the California Cancer Registry and California Department of Public Health's Center for Health Statistics, and [...]

Menée à partir de données portant sur 5 853 femmes ménopausées ayant survécu jusqu'à 6 ans après un diagnostic de cancer du sein HR+ de stade précoce (durée médiane de suivi : 3 ans), cette étude évalue l'association entre la durée d'utilisation d'inhibiteurs d'aromatase et le risque à long terme de maladie cardiovasculaire ainsi que le risque de décès associé ou toutes causes confondues

Duration of aromatase inhibitor use and long-term cardiovascular risk in breast cancer survivors

Huang, Yuhan ; Kwan, Marilyn L ; Heckbert, Susan R ; Smith, Nicholas L ; Othus, Megan ; Laurent, Cecile A ; Roh, Janise M ; Rillamas-Sun, Eileen ; Lee, Valerie S ; Kolevska, Tatjana ; Cheng, Richard K ; Irribarren, Carlos ; Nguyen-Huynh, Mai ; Hershman, Dawn L ; Kushi, Lawrence H ; Greenlee, Heather

Background : There are limited data on duration of aromatase inhibitor (AI) and cardiovascular disease (CVD) risk in breast cancer (BC) survivors. We examined risk of CVD and mortality associated with duration of AI use in postmenopausal women with early-stage hormone receptor-positive BC. Methods : Postmenopausal women diagnosed with hormone receptor-positive BC (n = 5,853) who used an AI were included. Cause-specific hazards models estimated hazard ratios (HRs) and 95% confidence intervals [...]

Menée aux Etats-Unis à partir de données de 22 registres des cancers portant sur 1 123 658 patientes atteintes d'un cancer du sein invasif diagnostiqué entre 2010 et 2019, cette étude examine les tendances de l'incidence de la maladie de manière globale et par sous-type moléculaire, âge et origine ethnique

Incidence Rate Trends of Breast Cancer Overall and by Molecular Subtype by Race and Ethnicity and Age

Li, Noelani H. Y. ; Li, Christopher I.

Importance : Black and Hispanic women in the US experience higher incidence rates of aggressive molecular subtypes of breast cancer, including triple-negative disease. However, how these rates are changing, particularly across different age groups, has not been well documented. Objective : To assess changes in overall and subtype-specific breast cancer incidence rates in the US by age and race and ethnicity. Design, Setting, and Participants : This cohort study used Surveillance, Epidemiology, [...]

A partir d'une revue systématique de la littérature publiée entre 2008 et 2023 (19 articles), cette étude identifie des outils et des méthodes permettant d'identifier les besoins sociaux des patients atteints d'un cancer

Screening for comprehensive social needs in patients with cancer: a narrative review

Arana, Isabel ; Liu, Raymond ; Kushi, Lawrence ; Hahn, Erin ; Ragavan, Meera

Background : Patients with cancer who report social needs have worse quality of life, lower healthcare access, and suboptimal health outcomes. However, screening for social needs does not happen systematically and successful screening tools, strategies, and workflows have seldom been described. The downstream effects of screening including resource navigation have also not been well characterized. This objective of this narrative review was to fill these gaps. Methods : Two investigators [...]

Menée aux Etats-Unis, cette étude examine l'association entre la participation à des essais cliniques, le coût des anticancéreux et la performance des pratiques en cancérologie dans le cadre de l'"Oncology Care Model", un modèle de paiement (alternatif au système Medicare) dont l'objectif visait à réduire les coûts tout en améliorant les soins

The association between clinical trial participation, drug costs, and performance in the Oncology Care Model (OCM)

Canavan, Maureen E ; Westvold, Sarah ; Csik, Valerie ; Franks, Jeffrey ; Rocque, Gabrielle ; Gross, Cary P ; Adelson, Kerin B

It has long been assumed that academic oncology practices are disadvantaged in value-based payment programs, due to patient complexity and research costs. This assumption not been tested. The Oncology Care Model (OCM) was a Medicare alternative payment model, which sought to curb costs while improving care. We assessed the impact of clinical trial (CT) participation on two outcomes: 1. cost and 2. practice performance among three participating NCI designated cancer centers using a random [...]

Menée aux Etats-Unis à partir de données du registre des cancers du Massachusetts et de bases de demandes de remboursement portant sur 6 279 personnes ayant bénéficié d'une assurance santé (privée, Medicaid ou Medicare) et décédées en 2014 d'un cancer (colorectal, poumon, sein ou prostate) diagnostiqué entre 2010 et 2013, cette étude évalue l'association entre l'utilisation de soins palliatifs ambulatoires avant le décès et l'intensité ainsi que la variation des soins de fin de vie en fonction des réseaux fournisseurs régionaux

Outpatient palliative care and end-of-life care intensity: Linking Massachusetts cancer registry with All-Payer claims

Keating, Nancy L ; Weissman, Joel S ; Wright, Alexi A ; Wolf, Robert ; Gershman, Susan ; Knowlton, Richard ; Ayanian, John Z

Background : Early palliative care is associated with better outcomes for patients with advanced-stage cancers. Using a novel data linkage, we assessed outpatient palliative care use before death and its association with end-of-life care intensity and variation across eight provider networks. Methods : We linked Massachusetts Cancer Registry and the All-Payer Claims Database for individuals with commercial insurance, Medicaid or Medicare Advantage diagnosed with colorectal, lung, prostate, and [...]

A partir d'une revue systématique de la littérature publiée jusqu'en janvier 2023 (58 études), cette méta-analyse identifie des outils d'évaluation de la fragilité, évalue leur performance et examine l'association entre le niveau de fragilité des patients et les résultats thérapeutiques

Frailty and outcomes in adults undergoing systemic anti-cancer treatment: a systematic review and meta-analysis

Pearce, Jessica ; Martin, Sally ; Heritage, Sophie ; Khoury, Emma G ; Kucharczak, Joanna ; Nuamek, Thitikorn ; Cairns, David A ; Velikova, Galina ; Richards, Suzanne H ; Clegg, Andrew ; Gilbert, Alexandra

It is increasingly recognised that frailty should be assessed and considered in treatment decision-making in patients with cancer. This review and meta-analysis synthesises existing evidence evaluating the association between baseline frailty and Systemic Anti-Cancer Treatment (SACT) outcomes in adults with cancer.Five databases were systematically searched from database inception to January 2023 to identify prognostic factor studies (cohort/case-control design) reporting the associations [...]